Headwinds ranging from an expected renewal of political wrangling over the price of prescription drugs to increasing pressure on sales of established treatments have largely, but not entirely, kept pharmaceutical companies from enjoying the increases of their biotech counterparts, as reflected in the share prices of exchange-traded funds (ETFs) consisting of pharma equities.